165 related articles for article (PubMed ID: 22281794)
1. Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy.
Zafarana G; Ishkanian AS; Malloff CA; Locke JA; Sykes J; Thoms J; Lam WL; Squire JA; Yoshimoto M; Ramnarine VR; Meng A; Ahmed O; Jurisica I; Milosevic M; Pintilie M; van der Kwast T; Bristow RG
Cancer; 2012 Aug; 118(16):4053-62. PubMed ID: 22281794
[TBL] [Abstract][Full Text] [Related]
2. NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy.
Locke JA; Zafarana G; Ishkanian AS; Milosevic M; Thoms J; Have CL; Malloff CA; Lam WL; Squire JA; Pintilie M; Sykes J; Ramnarine VR; Meng A; Ahmed O; Jurisica I; van der Kwast T; Bristow RG
Clin Cancer Res; 2012 Jan; 18(1):308-16. PubMed ID: 22048240
[TBL] [Abstract][Full Text] [Related]
3. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
[TBL] [Abstract][Full Text] [Related]
4. Allelic loss of the loci containing the androgen synthesis gene, StAR, is prognostic for relapse in intermediate-risk prostate cancer.
Locke JA; Zafarana G; Malloff CA; Lam WL; Sykes J; Pintilie M; Ramnarine VR; Meng A; Ahmed O; Jurisica I; Guns ET; van der Kwast T; Milosevic M; Bristow RG
Prostate; 2012 Sep; 72(12):1295-305. PubMed ID: 22213075
[TBL] [Abstract][Full Text] [Related]
5. The combination of PTEN deletion and 16p13.3 gain in prostate cancer provides additional prognostic information in patients treated with radical prostatectomy.
Bramhecha YM; Rouzbeh S; Guérard KP; Scarlata E; Brimo F; Chevalier S; Hamel L; Aprikian AG; Lapointe J
Mod Pathol; 2019 Jan; 32(1):128-138. PubMed ID: 30140035
[TBL] [Abstract][Full Text] [Related]
6. Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer.
Ishkanian AS; Zafarana G; Thoms J; Bristow RG
Acta Oncol; 2010 Oct; 49(7):888-94. PubMed ID: 20590366
[TBL] [Abstract][Full Text] [Related]
7. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB
Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
[TBL] [Abstract][Full Text] [Related]
8. NBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer.
Berlin A; Lalonde E; Sykes J; Zafarana G; Chu KC; Ramnarine VR; Ishkanian A; Sendorek DH; Pasic I; Lam WL; Jurisica I; van der Kwast T; Milosevic M; Boutros PC; Bristow RG
Oncotarget; 2014 Nov; 5(22):11081-90. PubMed ID: 25415046
[TBL] [Abstract][Full Text] [Related]
9. 8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy.
Fromont G; Godet J; Peyret A; Irani J; Celhay O; Rozet F; Cathelineau X; Cussenot O
Hum Pathol; 2013 Aug; 44(8):1617-23. PubMed ID: 23574779
[TBL] [Abstract][Full Text] [Related]
10. Exploring prostate cancer genome reveals simultaneous losses of PTEN, FAS and PAPSS2 in patients with PSA recurrence after radical prostatectomy.
Ibeawuchi C; Schmidt H; Voss R; Titze U; Abbas M; Neumann J; Eltze E; Hoogland AM; Jenster G; Brandt B; Semjonow A
Int J Mol Sci; 2015 Feb; 16(2):3856-69. PubMed ID: 25679447
[TBL] [Abstract][Full Text] [Related]
11. Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients.
Ribeiro FR; Henrique R; Martins AT; Jerónimo C; Teixeira MR
Eur Urol; 2007 Jul; 52(1):116-25. PubMed ID: 17070983
[TBL] [Abstract][Full Text] [Related]
12. Genetic markers associated with early cancer-specific mortality following prostatectomy.
Liu W; Xie CC; Thomas CY; Kim ST; Lindberg J; Egevad L; Wang Z; Zhang Z; Sun J; Sun J; Koty PP; Kader AK; Cramer SD; Bova GS; Zheng SL; Grönberg H; Isaacs WB; Xu J
Cancer; 2013 Jul; 119(13):2405-12. PubMed ID: 23609948
[TBL] [Abstract][Full Text] [Related]
13. PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance.
Trock BJ; Fedor H; Gurel B; Jenkins RB; Knudsen BS; Fine SW; Said JW; Carter HB; Lotan TL; De Marzo AM
Mod Pathol; 2016 Jul; 29(7):764-71. PubMed ID: 27080984
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer.
Tsuchiya N; Slezak JM; Lieber MM; Bergstralh EJ; Jenkins RB
Genes Chromosomes Cancer; 2002 Aug; 34(4):363-71. PubMed ID: 12112525
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma.
Sato K; Qian J; Slezak JM; Lieber MM; Bostwick DG; Bergstralh EJ; Jenkins RB
J Natl Cancer Inst; 1999 Sep; 91(18):1574-80. PubMed ID: 10491435
[TBL] [Abstract][Full Text] [Related]
16. Single-cell genetic analysis reveals insights into clonal development of prostate cancers and indicates loss of PTEN as a marker of poor prognosis.
Heselmeyer-Haddad KM; Berroa Garcia LY; Bradley A; Hernandez L; Hu Y; Habermann JK; Dumke C; Thorns C; Perner S; Pestova E; Burke C; Chowdhury SA; Schwartz R; Schäffer AA; Paris PL; Ried T
Am J Pathol; 2014 Oct; 184(10):2671-86. PubMed ID: 25131421
[TBL] [Abstract][Full Text] [Related]
17. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.
Böttcher R; Kweldam CF; Livingstone J; Lalonde E; Yamaguchi TN; Huang V; Yousif F; Fraser M; Bristow RG; van der Kwast T; Boutros PC; Jenster G; van Leenders GJLH
BMC Cancer; 2018 Jan; 18(1):8. PubMed ID: 29295717
[TBL] [Abstract][Full Text] [Related]
18. Assessment of MYC/PTEN Status by Gene-Protein Assay in Grade Group 2 Prostate Biopsies.
Salles DC; Vidotto T; Faisal FA; Tosoian JJ; Guedes LB; Muranyi A; Bai I; Singh S; Yan D; Shanmugam K; Lotan TL
J Mol Diagn; 2021 Aug; 23(8):1030-1041. PubMed ID: 34062284
[TBL] [Abstract][Full Text] [Related]
19. Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations.
Gandellini P; Casiraghi N; Rancati T; Benelli M; Doldi V; Romanel A; Colecchia M; Marenghi C; Valdagni R; Demichelis F; Zaffaroni N
Eur Urol Oncol; 2019 May; 2(3):277-285. PubMed ID: 31200842
[TBL] [Abstract][Full Text] [Related]
20. TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair.
Dal Pra A; Lalonde E; Sykes J; Warde F; Ishkanian A; Meng A; Maloff C; Srigley J; Joshua AM; Petrovics G; van der Kwast T; Evans A; Milosevic M; Saad F; Collins C; Squire J; Lam W; Bismar TA; Boutros PC; Bristow RG
Clin Cancer Res; 2013 Sep; 19(18):5202-9. PubMed ID: 23918607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
